Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia

Vladimir Vainstein, Christopher A. Eide, Thomas O'Hare, Ofir Shukron, Brian J. Druker

Research output: Contribution to journalArticle

7 Scopus citations

Fingerprint Dive into the research topics of 'Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds